Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kushner, B. H.
Right arrow Articles by Cheung, N.-K. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kushner, B. H.
Right arrow Articles by Cheung, N.-K. V.
Journal of Clinical Oncology, Vol 19, Issue 14 (July), 2001: 3397-3405
© 2001 American Society for Clinical Oncology

Extending Positron Emission Tomography Scan Utility to High-Risk Neuroblastoma: Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography as Sole Imaging Modality in Follow-Up of Patients

By Brian H. Kushner, Henry W.D. Yeung, Steven M. Larson, Kim Kramer, Nai-Kong V. Cheung

From the Departments of Medical Imaging and Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY., Submitted January 2, 2001; accepted April 4, 2001.

Address reprint requests to Brian H. Kushner, MD, Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021; email: kushnerb{at}mskcc.org

PURPOSE: Although positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (18F-FDG) has a major impact on the treatment of adult cancer, the reported experience with extracranial tumors of childhood is limited. We describe a role for PET in patients with neuroblastoma (NB).

PATIENTS AND METHODS: In 51 patients with high-risk NB, 92 PET scans were part of a staging evaluation that included iodine-123 or iodine-131 metaiodobenzylguanidine (MIBG) scan, bone scan, computed tomography (and/or magnetic resonance imaging), urine catecholamine measurements, and bone marrow (BM) examinations. The minimum number of tests sufficient to detect NB was determined.

RESULTS: Of 40 patients who were not in complete remission, only 1 (2.5%) had NB that would have been missed had a staging evaluation been limited to PET and BM studies, and 13 (32.5%) had NB detected by PET but not by BM and urine tests. PET was equal or superior to MIBG scans for identifying NB in soft tissue and extracranial skeletal structures, for revealing small lesions, and for delineating the extent and localizing sites of disease. In 36 evaluations of 22 patients with NB in soft tissue, PET failed to identify only two long-standing MIBG-negative abdominal masses. PET and MIBG scans showed more skeletal lesions than bone scans, but the normally high physiologic brain uptake of FDG blocked PET visualization of cranial vault lesions. Similar to MIBG, FDG skeletal uptake was diffusely increased with extensive or progressing BM disease but faint or absent with minimal or nonprogressing BM disease.

CONCLUSION: In the absence or after resolution of cranial vault lesions, and once the primary tumor is resected, PET and BM tests suffice for monitoring NB patients at high risk for progressive disease in soft tissue and bone/BM.




This article has been cited by other articles:


Home page
JCOHome page
H. J.L.M. Timmers, A. Kozupa, C. C. Chen, J. A. Carrasquillo, A. Ling, G. Eisenhofer, K. T. Adams, D. Solis, J. W.M. Lenders, and K. Pacak
Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma
J. Clin. Oncol., June 1, 2007; 25(16): 2262 - 2269.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
K. Pacak, G. Eisenhofer, and D. S. Goldstein
Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography
Endocr. Rev., August 1, 2004; 25(4): 568 - 580.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
B. H. Kushner
Neuroblastoma: A Disease Requiring a Multitude of Imaging Studies
J. Nucl. Med., July 1, 2004; 45(7): 1172 - 1188.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
B. H. Kushner, S. D.J. Yeh, K. Kramer, S. M. Larson, and N.-K. V. Cheung
Impact of Metaiodobenzylguanidine Scintigraphy on Assessing Response of High-Risk Neuroblastoma to Dose-Intensive Induction Chemotherapy
J. Clin. Oncol., March 15, 2003; 21(6): 1082 - 1086.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2001 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online